Zanfina Ademi: Routine Lp(a) Testing as a Cost-Effective Step Toward Precision Cardiovascular Prevention
FH Europe Foundation shared an insightful post from Professor Zanfina Ademi on LinkedIn:
“Lp(a): A Missed Opportunity in Cardiovascular Prevention
Despite its strong genetic link to ASCVD and its prevalence in 1 in 5 people, Lp(a) raemains under-tested in clinical practice. A new study in Atherosclerosis highlights both the clinical relevance and cost-effectiveness of routine Lp(a) testing, strengthening the case for its integration into cardiovascular risk assessment.
Led by Monash University, supported by global experts and initiated by FH Europe Foundation, the study shows:
- Routine Lp(a) testing is cost-saving across multiple health systems
- It enables earlier intervention with existing therapies
- It supports value-based care and equitable access to precision prevention
The findings align with the Brussels International Declaration, a 2025 global policy initiative urging governments to include Lp(a) in national cardiovascular screening programs.
Prof. Zanfina Ademi, senior author and health economist at Monash: “From both a public health and economic standpoint, this is a highly cost-effective intervention targeting a major gap in cardiovascular prevention.”
Stay updated with Hemostasis Today.
-
Nov 1, 2025, 16:45Erin VanDyke: This Month Was Full of Meaningful VTE Moments
-
Nov 1, 2025, 14:14Congratulations to South Africa’s first WSO Certified Essential Stroke Centers!
-
Oct 31, 2025, 14:17When Stories Save Lives: Reza Shojaei Shares Blood and Plasma Pulse Newest Issue
-
Oct 31, 2025, 13:34Charlotte Pilling Invites You to ''Women in Hematology'' US Focus Meeting
-
Oct 30, 2025, 12:12Laura Ceci Galanos Reflects on WSC 2025
-
Oct 31, 2025, 13:47Bethany Brown and Colleagues Present Recommendations on DEHP Alternatives
-
Oct 30, 2025, 07:52Haemophilia B - An illustrative review of current challenges and opportunities
-
Oct 30, 2025, 05:14Umberto Pensato on Reperfusion Outcomes in Stroke
-
Oct 29, 2025, 07:39Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction
-
Oct 29, 2025, 07:38Thijs van Haaps and Team Show That Andexanet Alfa May Go Beyond Apixaban and Rivaroxaban
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 1, 2025, 17:04Ozlem Fidanci: Recognizing The Signs of a Stroke Can Save Someone You Love
-
Nov 1, 2025, 15:51Gülşah Türkoğlu: On World Stroke Day, We Came Together to Commemorate This Important Global Health Occasion
-
Nov 1, 2025, 15:05Nusaiba Masnurah Delivered A Speech on Surviving Thrombotic Events Werfen’s EEMEA Seminars
-
Nov 1, 2025, 14:47Rob Verhaeren at WSC 2025: Discover How Philips Technology Helps Accelerate Stroke Response
-
Nov 1, 2025, 13:58Rena Hirani Awarded the Inaugural James Isbister Prize at the Blood ISBT 2025